Avalon Ventures XI, L.P.'s Form 4 filing
Janux Therapeutics, Inc. (JANX) · filed Nov 13, 2023
- Accession no.
- 0001209191-23-055083
- Filed
- Nov 13, 2023, 7:11 PM ET
- Trade date
- Nov 13, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $4.99M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Avalon Ventures XI, L.P.CIK 0001652901 | 10% Owner |
| Avalon BioVentures SPV I, L.P.CIK 0001844550 | 10% Owner |
| Avalon BioVentures I, LPCIK 0001873935 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 13, 2023 | Common Stock | PPurchaseAcquired | +849,854 | $5.87 | +$4,988,642.98 | 849,854 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.